See the development of manufacturer's prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>
- AMNOG-Monitor Analysis · Pricing · Prediction (325 KB)
Identify decision-paths and trends in early benefit assessment. The AMNOG monitor is indispensable for managers and decision-makers in market access, pricing and reimbursement.
Dear readers of the AMNOG Monitor,
With a total of more than 130 early benefit assessment procedures in 2021, the pharmaceutical industry has been showing its innovative strength and the G-BA is demonstrating its ability to act even during a pandemic.
We, too, have implemented a whole range of new options for analyses in the AMNOG Monitor. We have already familiarised our customers with these new possibilities in various training courses. Please feel free to contact us if you need training or have any questions. We are constantly striving to make the AMNOG Monitor user-friendlier and welcome your suggestions for further development.
In September 2021, another 16 G-BA resolutions on early benefit assessments were passed, so that a total of 634 procedures are now completed. The results of the new resolutions are shown in the table below.
Resolutions September 2021
Changes to reimbursement prices of AMNOG products were seen in September 2021 for Abemaciclib (Verzenios®), Andexanet alfa (Ondexxya®), Damoctocog alfa pegol (Jivi®), Dulaglutid (Trulicity®), Elosulfase alfa (Vimizim®), Ixekizumab (Taltz®), Luspatercept (Reblozyl®), Riociguat (Adempas®), Ropeginterferon alfa-2b (Besremi®) and for Talazoparib (Talzenna®).
Dr Johannes Hankowitz and Christian Rieke